Menopause and What to Do About It

Written by BIH of Decatur on . Posted in Menopausal Research, Women

Most women do not like the effects of menopause.  That is not news.  Who would want to have hot flashes, vaginal dryness, and depression?  The really sad thing is that so very many women now are on medications for depression, anxiety and sleep in an effort to counter the horrible consequences of loss of hormones.  This does not have to happen.  Your declining hormones can be replaced easily without the documented side effects of synthetic non-natural hormones.

Menopause is a condition in women resulting in loss of sex hormones.  Testosterone begins to drop off in most women by age 30.  Progesterone declines at age 35.  And finally estradiol declines by age 40 in most women.  Eight percent of women will go through menopause before age 40.
Menopause is defined as not having a period for 6 to 12 months.  Another indication is when follicular stimulating hormone (FSH), a pituitary hormone, goes up to 23 whether she is menstruation or not.   Women may have significant hot flashes and increased sexual dysfunction, as well as depressive symptoms which can cause psychosocial impairment.  Portrait of mature woman sitting in countryside

The commonly used synthetic conjugated estrogen for menopausal symptoms has inherent problems, namely an increased incidence of breast and cervical cancer, blood clots and heart disease as noted by the Women’s Health Initiative.  The erroneous assumptions of this study implied that ALL estrogens given with progestin or progesterone produce an increase in breast cancer.  Oral hormone replacement therapy cannot produce normal, steady physiologic levels of estrogen and maintain the physiologic ratio of estradiol to estrone 2:1.(1)

Bio-identical hormone replacement is safer than synthetic artificial hormones.  There have never been noted the health risks as with the use of synthetic estrogens especially when used with synthetic progestin.  Replacing the natural hormones we once had when we were 20 can be protective.  Dr. Gino Tutera performed a study of 976 women over a period of 10 years (1992 through 2002) who all had the bio-equivalent pellet hormone insertions of estradiol and/or testosterone.  After 10 years there was only 1 lady who had breast cancer.  The patient with breast cancer was discovered less than 1 year after the insertion.  Most likely she already she had a microscopic cancer before the implants.  There were no cases of ovarian cancer, and only one case of endometrial cancer.  The endometrial cancer was found after the patient’s first six months in therapy.  The patient had Stage 3 Grade 1, well differentiated tumor who has remained disease free three years after therapy.(2)

These were patients in the years of a woman’s life where she would most likely find breast cancer.  With the law of averages one would expect to find 60 or 70 women from a study group like this to develop breast cancer over a 10 year period.
Subcutaneous bio-identical hormone replacement therapy with estradiol and testosterone with oral progesterone, imparts a protective physiologic environment that can reduce the risks of breast, endometrial and ovarian cancer.  We know that breast cancer is extremely rare in an 18-year-old.  An 18-year-old has normal levels of sex hormones to protect her.  Subcutaneous pellet therapy causes the release of minute amounts of estradiol steadily over a 24-hour period for up to 4 to 6 months giving a protective physiologic ratio of estradiol to estrone at 2:1.
Equally, ovarian cancer shows marked reduction in those on oral contraceptive therapy as noted in the National Nurses Study.  OC therapy produces suppression of serum FSH thereby halting follicular development.  This produces a dormant state in the ovaries therefore a lower risk of ovarian cancer.

Natural Pellet Bio-Identical Hormone Replacement Therapy more closely simulates the sought-after healthy state found in young men and women.

Sources:

1. Thom, M.H.; Studd, J.W.W., Estrogen and Testosterone Implant Therapy.  Whitehead, M., Campbell , Estrogen and the Menopause. Queensboorough, Kent;  Abbott Laboratories, Ltd., 1978: 85-88.

2. Tutera, G. Subcutaneous hormone therapy reduces breast cancer incidence. Rediscover You. Scottsdale, AZ.

Trackback from your site.

Leave a comment